p27 expression and proliferation in gastrointestinal stromal tumors

Turkish Journal of Gastroenterology

Volumn 14, Issue 2, 2003, Pages 132-137

  Gelen, M Tekinalp ^a,b   Elpek, G Özlem ^a   Aksoy, N Hikmet ^a   Öǧüş, Mehmet ^a   Süleymanlar, Inci ^a   Işitan, Fahri ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

^b Patoloji Anabilim Dali   (Turkey)

Author keywords

Gastrointestinal stromal tumors; Ki 67; p27; Proliferation

Indexed keywords

KI 67 ANTIGEN; PROTEIN P27; TUMOR MARKER;

ADULT; ARTICLE; BENIGN TUMOR; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIGESTIVE SYSTEM CANCER; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MALE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TISSUE SECTION; TUMOR CELL;

ADULT; FEMALE; GASTRIC MUCOSA; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; PROLIFERATING CELL NUCLEAR ANTIGEN;

EID: 0042026644     PISSN: 13004948     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Yu CC, Fletcher CD, Newman PL, et al. A comparison of proliferating cell nuclear antigen (PCNA) immunostaining, nucleolar organizing region (AgNOR) staining, and histological grading in gastrointestinal stromal tumours. J Pathol 1992; 166: 147-52.
2. Sbaschnig RJ, Cunningham RE, Sobin LH, O'Learly TJ. Proliferating-cell nuclear antigen immunocytochemistry in the evaluation of gastrointestinal smooth-muscle tumors. Mod Pathol 1994; 7: 780-83.
3. Hillemanns M, Hofler H. Current classification of gastrointestinal stromal tumors. Chirurg 2000; 71:1327-34.
4. Rudolph P, Gloeckner K, Parwaresch R, et al. Immunophenotype, proliferation, DNA ploidy, and biological behaviour of gastrointestinal stromal tumors: a multivariate clinicopathologic study. Hum Pathol 1998; 29: 791-800.
5. Carrillo R, Candia A, Rodriguez-Peralto JL, Caz V. Prognostic significance of DNA ploidy and proliferative index (MIB-1 index) in gastrointestinal stromal tumours. Hum Pathol 1997; 28: 160-65.
6. Panizo-Santos A, Sola I, Vega F, et al. Predicting metastatic risk of gastrointestinal stromal tumors: role of cell proliferation and cell cycle regulatory proteins. Int J Surg Pathol 2000; 8: 133-44.
7. Scherr CJ. Cancer cell cycles. Science 1996; 274: 1672-77.
8. Hirama T, Koeffler HP. Role of cyclin-dependent kinase inhibitors in the development of cancer. Blood 1995; 86: 841-54.
9. Polyak K, Kato JY, Solomon MJ, et al. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 1994, 8: 9-22.
10. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994, 78:67-74.
11. Reynisdóttir I, Polyak K, Iavarone A, Massagué J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev 1995; 9:1831-45.
12. Soos TJ, Kiyokawa H, Yan JS, et al. Formation of p27-CDK complexes during the human mitotic cell cycle. Cell Growth Differ 1996; 7:135-46.
13. Cheng M, Sexl V, Sherr CJ, Roussel MF. Assembly of cyclin D-dependent kinase and titration of p27/KIP1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc Natl Acad Sci USA 1998; 95:1091-96.
14. Pagano M, Tam SW, Theodoras AM, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995; 269:682-85.
15. Hengst L, Reed SI. Translational control of p27Kip1 accumulation during the cell cycle. Science 1996; 271:1861-64.
16. Nourse J, Firpo E, Flanagan WM, et al. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994; 372:570-73.
17. Catzavelos C, Bhatacharya N, Ung YC, et al. Decreased levels of the cell-cycle inhibitor p27(Kipl) protein: prognostic implications in primary breast cancer. Nat Med 1997; 3: 227-30.
18. Esposito V, Baldi A, Luca A, et al. Prognostic role of the cyclin-dependent inhibitor p27 in non-small cell lung cancer. Cancer Res 1997; 57: 3381-85.
19. Porter PL, Malone KE, Heagerty PJ, et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997; 3: 222-25.
20. Sanchez-Beato M, Saez AI, Martinez-Montero JC, et al. Cyclin-dependent kinase inhibitor p27(KIP1) in lymphoid tissue: p27(KIP1) expression is inversely proportional to the proliferative index. Am J Pathol 1997; 151:151-60.
21. Lloyd RV, Jin L, Qian X, Kulig E. Aberrant p27kip1 expression in endocrine and other tumours. Am J Pathol 1997; 150:401-7.
22. Rose DSC, Maddox PH, Brown CD. Which proliferation marker for routine immunohistology? A comparison of five antibodies. J Clin Pathol 1994; 47:1010-14.
23. Sherr CJ. G1 phase progression: cycling on cue. Cell 1994; 79: 551-55.
24. Inagaki H, Nagasaka T, Otsuka T, et al. Association of SYT-SSX fusion types with proliferative activity and prognosis in synovial sarcoma. Mod Pathol 2000; 13: 482-88.
25. Kourea HP, Cordon-Cardo C, Dudas M, et al. Expression of p27(kip) and other cell cycle regulators in malignant peripheral nerve sheath tumours and neurofibromas: the emerging role of p27(kip) in malignant transformation of neurofibromas. Am J Pathol 1999; 155: 1885-91.